Palatin Technologies, Inc. :PTN-US: Earnings Analysis: Q2, 2017 By the Numbers

Click here to see latest analysis Palatin Technologies, Inc. reports financial results for the quarter ended December 31, 2016. Analysis Summary numbers: Revenues of USD 0 million, Net Earnings of USD -10.03 million. The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless. … Read more

Pluristem Therapeutics, Inc. :PSTI-US: Earnings Analysis: Q2, 2017 By the Numbers

Click here to see latest analysis Pluristem Therapeutics, Inc. reports financial results for the quarter ended December 31, 2016. Analysis Summary numbers: Revenues of USD 0 million, Net Earnings of USD -6.61 million. The company employs relatively high amounts of assets (with a turnover of 0x compared to peer median of 0.04x) while generating profit … Read more

Pure Gold Mining, Inc. :PGM-CA: Earnings Analysis: Q3, 2017 By the Numbers

Click here to see latest analysis Pure Gold Mining, Inc. reports financial results for the quarter ended December 31, 2016. Analysis Summary numbers: Revenues of CAD 0 million, Net Earnings of CAD -6.91 million. The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover … Read more

Nemaska Lithium, Inc. :NMX-CA: Earnings Analysis: Q2, 2017 By the Numbers

Click here to see latest analysis Nemaska Lithium, Inc. reports financial results for the quarter ended December 31, 2016. Analysis Summary numbers: Revenues of CAD 0 million, Net Earnings of CAD -2.75 million. The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless. … Read more

Levon Resources Ltd. :LVN-CA: Earnings Analysis: Q3, 2017 By the Numbers

Click here to see latest analysis Levon Resources Ltd. reports financial results for the quarter ended December 31, 2016. Analysis Summary numbers: Revenues of CAD 0 million, Net Earnings of CAD -1.10 million. The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless. … Read more

Genocea Biosciences, Inc. :GNCA-US: Earnings Analysis: Q4, 2016 By the Numbers

Click here to see latest analysis Genocea Biosciences, Inc. reports financial results for the quarter ended December 31, 2016. Analysis Summary numbers: Revenues of USD 0 million, Net Earnings of USD -16.03 million. The company does not seem to have a viable operating strategy as is evident from low net profit margins (currently -21,094.89% vs. … Read more

ESSA Pharma, Inc. :EPI-CA: Earnings Analysis: Q1, 2017 By the Numbers

Click here to see latest analysis ESSA Pharma, Inc. reports financial results for the quarter ended December 31, 2016. Analysis Summary numbers: Revenues of CAD 0 million, Net Earnings of CAD 1.95 million. The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless. … Read more

Ardelyx, Inc. :ARDX-US: Earnings Analysis: Q4, 2016 By the Numbers

Click here to see latest analysis Ardelyx, Inc. reports financial results for the quarter ended December 31, 2016. Analysis Summary numbers: Revenues of USD 0 million, Net Earnings of USD -31.28 million. The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless. ARDX-US‘s … Read more

Regeneron Pharmaceuticals, Inc.: A look at fundamentals

Capitalcube gives Regeneron Pharmaceuticals, Inc. a score of 81. Our analysis is based on comparing Regeneron Pharmaceuticals, Inc. with the following peers – Amgen Inc., Alnylam Pharmaceuticals, Inc, Biogen Inc., pSivida Corp., Johnson & Johnson, Ophthotech Corp., Sanofi Sponsored ADR and Novartis AG Sponsored ADR (AMGN-US, ALNY-US, BIIB-US, PSDV-US, JNJ-US, OPHT-US, SNY-US and NVS-US). Investment … Read more